Recently Featured

Roche’s ctDNA-guided approach in post-surgical bladder cancer pays off with Tecentriq nod

June 6, 2026
Roche has secured FDA approval for the expanded use of Tecentriq in post-surgical bladder cancer, leveraging its innovative ctDNA-guided strategy in collaboration with Natera’s Signatera as a companion diagnostic. This approval marks a significant milestone in the treatment landscape for bladder cancer, where precision medicine is increasingly becoming a focal point in therapeutic development. The…

Aardvark to Unblind Rare Disease Trial Following Clinical Hold

June 6, 2026
Aardvark Pharmaceuticals is set to unblind its rare disease trial after receiving a full clinical hold from the FDA on its candidate. This decision comes after the agency raised concerns regarding the safety profile of the drug, which has significant implications for Aardvark’s development timeline and investor confidence. The unblinding process will allow the company…

New Ebola Outbreak Confirmed in Congo’s Ituri Province with 65 Deaths

June 5, 2026
KINSHASA, Congo — Africa’s top public health body has confirmed a new Ebola outbreak in Congo’s remote Ituri province, reporting 246 suspected cases and 65 deaths to date. This alarming development underscores the persistent threat of Ebola in the region, which has historically faced multiple outbreaks. The fatalities and suspected infections are concentrated primarily in…

Beverly Davidson Advances Huntington’s Disease Gene Therapy at ASGCT 2026

June 5, 2026
BOSTON – Geneticist Beverly Davidson, PhD, was honored with the 2026 Outstanding Achievement Award from the American Society of Gene and Cell Therapy (ASGCT) for her significant contributions to gene therapy research. Currently serving as the chief scientific strategy officer at the Children’s Hospital of Philadelphia (CHOP), Davidson’s work is pivotal in the development of…

Ongoing Cases